Henrijette Richter

Henrijette Richter currently works at Asceneuron SA, as Vice Chairman, iOmx Therapeutics AG, as Vice Chairman-Supervisory Board from 2019, Delinia, Inc., as Director, NodThera Ltd., as Director from 2019, Nitrase Therapeutics, Inc., as Director, Redona Therapeutics, Inc., as Director from 2019, Comet Therapeutics, Inc., as Director from 2017, Muna Therapeutics ApS, as Director, Mozart Therapeutics, Inc., as Director, and Sofinnova Partners SAS, as Managing Partner from 2017.
Dr. Richter also formerly worked at Avilex Pharma ApS, as Chairman, Affinicon ApS, as Chairman, Novo Holdings A, as Investment Director, MycoTeQ A, as Director, EpiTherapeutics ApS, as Director, Novo Seeds, as Investment Director from 2007 to 2014, Cytoguide ApS, as Director, Strategic Partners A, as Director, Nanoference ApS, as Director, and KDventures AB, as Independent Director from 2014 to 2017.
Dr. Richter received her graduate degree in 1999 and doctorate degree in 2002 from the University of Copenhagen.